A Study of NeoRecormon in Patients With Chronic Kidney Disease.
|ClinicalTrials.gov Identifier: NCT00437723|
Recruitment Status : Completed
First Posted : February 21, 2007
Last Update Posted : May 14, 2009
|Condition or disease||Intervention/treatment||Phase|
|Anemia||Drug: epoetin beta [NeoRecormon]||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||90 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label Study to Investigate the Effect of NeoRecormon on Hemoglobin Level and Renal Function in Patients With Chronic Kidney Disease, Stage 2-4|
|Study Completion Date :||April 2008|
Drug: epoetin beta [NeoRecormon]
At a dose to achieve and maintain an Hb level of 120-135g/dL.
|No Intervention: 2|
- Hb level, decline in renal function, 24h proteinuria, creatinine clearance. [ Time Frame: Throughout study ]
- SAEs, AEs leading to withdrawal, AEs related to NeoRecormon. [ Time Frame: Throughout study ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00437723
|Belgrade, Serbia, 11000|
|Novi Sad, Serbia, 21000|
|Study Director:||Clinical Trials||Hoffmann-La Roche|